.png){kind=logo}
SEMAGLUTIDE
Tirzepatide (MOUNJARO)
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist, currently fast-tracked for FDA approval as a weight loss treatment
Semaglutide (Ozempic/Wegovy)
FDA approved semaglutide for weight loss in 2021 under the brand name Wegovy.
​
Semaglutide is a glucagon-like peptide (GLP-1) analog. GLP-1 is a peptide hormone produced in the small intestine that stimulates insulin secretion and inhibits glucagon secretion, slows gastric emptying, and regulates appetite – all of which aid in healthy and effective weight loss.
Weight loss
Although some of these medications are not yet FDA approved for weight loss, the results are well documented and undeniable. Evidence shows the new class of drugs are far more effective than prior obesity medications. The demand has surged for these medications because of its impressive abilities. Many can benefit with this medication, this may include patients with abnormal blood glucose, patients with prediabetes or metabolic syndrome, or in overweight patients (BMI > 27) with at least one-weight related condition, such as type 2 diabetes or high blood pressure, as well as obese patients (BMI > 30).